BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood 2020;136:480-8. [PMID: 32374875 DOI: 10.1182/blood.2020005674] [Cited by in Crossref: 11] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Chonat S, Stowell SR. A virtuosic CADENZA played by sutimlimab. Blood 2022;140:933-5. [PMID: 36048476 DOI: 10.1182/blood.2022017284] [Reference Citation Analysis]
2 Ehrlich S, Wichmann C, Spiekermann K. [Autoimmune haemolytic anemias]. Dtsch Med Wochenschr 2022;147:1243-50. [PMID: 36126922 DOI: 10.1055/a-1767-8281] [Reference Citation Analysis]
3 Fatone MC, Cirasino L. Practical therapy for primary autoimmune hemolytic anemia in adults. Clin Exp Med 2022. [PMID: 35980482 DOI: 10.1007/s10238-022-00869-2] [Reference Citation Analysis]
4 Krull A, Thompson T, Strasburg D, DiGuardo M, Jacob EK. How do I warm HPC(A) products to maximize cell viability in the setting of cold agglutinin disease? Transfusion 2022. [PMID: 35946488 DOI: 10.1111/trf.17038] [Reference Citation Analysis]
5 Berentsen S, Barcellini W, D'Sa S, Jilma B. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom? Immunotherapy 2022. [PMID: 35946351 DOI: 10.2217/imt-2022-0085] [Reference Citation Analysis]
6 Berentsen S, Tjønnfjord GE. Current treatment options in cold agglutinin disease: B-cell directed or complement directed therapy? Transfusion Medicine Reviews 2022. [DOI: 10.1016/j.tmrv.2022.05.001] [Reference Citation Analysis]
7 Hansen DL, Möller S, Frederiksen H. Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up. Eur J Haematol 2022. [PMID: 35276014 DOI: 10.1111/ejh.13764] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Ursule-Dufait C, Bengoufa D, Theodorou I, Villesuzanne C, Arnulf B. Heavy chain/light chain assay is a useful biomarker for diagnosis and management of patients with cold agglutinin disease. Br J Haematol 2022. [PMID: 35732557 DOI: 10.1111/bjh.18317] [Reference Citation Analysis]
9 Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng WJ, Choi JK, Chuang SS, Coupland SE, Czader M, Dave SS, de Jong D, Du MQ, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li XQ, Lim MS, Liu WP, Louissaint A Jr, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng SB, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022. [PMID: 35732829 DOI: 10.1038/s41375-022-01620-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
10 Fattizzo B, Barcellini W. Autoimmune hemolytic anemia: causes and consequences. Expert Rev Clin Immunol 2022;:1-15. [PMID: 35702053 DOI: 10.1080/1744666X.2022.2089115] [Reference Citation Analysis]
11 Gelbenegger G, Jaeger U, Fillitz M, D'sa S, Cartwright R, Shafer F, Wardecki M, Wang J, Schoergenhofer C, Jilma B. Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial. Br J Haematol. [DOI: 10.1111/bjh.18289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Xiao Z, Murakhovskaya I. Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics 2022;14:1035. [DOI: 10.3390/pharmaceutics14051035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Jacobs JW, Gisriel SD. Cold agglutinin syndrome in a patient with anaemia and beta-thalassemia trait. Transfus Med 2022. [PMID: 35415850 DOI: 10.1111/tme.12864] [Reference Citation Analysis]
14 Hwang SR, Saliba AN, Wolanskyj-Spinner AP. Immunotherapy-associated Autoimmune Hemolytic Anemia. Hematol Oncol Clin North Am 2022;36:365-80. [PMID: 35339260 DOI: 10.1016/j.hoc.2021.11.002] [Reference Citation Analysis]
15 Tvedt THA, Steien E, Øvrebø B, Haaverstad R, Hobbs W, Wardęcki M, Tjønnfjord GE, Berentsen SA. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. Am J Hematol 2022;97:E51-4. [PMID: 34778998 DOI: 10.1002/ajh.26409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Pratt G, El‐sharkawi D, Kothari J, D’sa S, Auer R, Mccarthy H, Krishna R, Miles O, Kyriakou C, Owen R. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline. Br J Haematol. [DOI: 10.1111/bjh.18036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
17 Campbell A, Podbury B, Yue M, Mollee P, Bird R, Hapgood G. The Role of a Routine Bone Marrow Biopsy in Autoimmune Hemolytic Anemia for the Detection of an Underlying Lymphoproliferative Disorder. Hemasphere 2022;6:e674. [PMID: 34938958 DOI: 10.1097/HS9.0000000000000674] [Reference Citation Analysis]
18 Patriquin CJ, Pavenski K. O, wind, if winter comes … will symptoms be far behind?: Exploring the seasonality (or lack thereof) and management of cold agglutinin disease. Transfusion 2021. [PMID: 34893982 DOI: 10.1111/trf.16765] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Röth A, Fryzek J, Jiang X, Reichert H, Patel P, Su J, Morales Arias J, Broome CM. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease. Transfusion 2021. [PMID: 34813663 DOI: 10.1111/trf.16745] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Joly F, Schmitt LA, Watson PAM, Pain E, Testa D. The Burden of Cold Agglutinin Disease on Patients’ Daily Life: An Online Survey of 50 American Patients (Preprint). JMIR Formative Research. [DOI: 10.2196/34248] [Reference Citation Analysis]
21 Iolascon A, Rivella S, Anagnou NP, Camaschella C, Swinkels D, Muckenthaler MU, Porto G, Barcellini W, Andolfo I, Risitano AM, Kattamis A, Cappellini MD, Taher AT, De Franceschi L, Rees D, Russo R, Tamary H, Stauder R, Girelli D. The EHA Research Roadmap: Anemias. Hemasphere 2021;5:e607. [PMID: 34522846 DOI: 10.1097/HS9.0000000000000607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Berentsen S. How I treat cold agglutinin disease. Blood 2021;137:1295-303. [PMID: 33512410 DOI: 10.1182/blood.2019003809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
23 Hansen DL, Berentsen S, Fattizzo B, Hansen PL, Barcellini W, Frederiksen H. Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy. Am J Hematol 2021;96:E262-5. [PMID: 33864697 DOI: 10.1002/ajh.26196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Signorelli SS, Oliveri Conti G, Carpinteri G, Lumera G, Fiore M, Dattilo G, Gaudio A, Ferrante M. Venous thromboembolism in hospital emergency room. A retrospective study on climatic effect. Environ Res 2021;197:110950. [PMID: 33737078 DOI: 10.1016/j.envres.2021.110950] [Reference Citation Analysis]
25 Baur K, Buser AS, Infanti L, Halter JP, Passweg JR, Holbro A. Immune cytopenia after allogeneic haematopoietic stem-cell transplantation: challenges, approaches, and future directions. Lancet Haematol 2021;8:e229-39. [PMID: 33636143 DOI: 10.1016/S2352-3026(20)30404-X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zaninoni A, Giannotta JA, Gallì A, Artuso R, Bianchi P, Malcovati L, Barcellini W, Fattizzo B. The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. Front Immunol 2021;12:649441. [PMID: 33732266 DOI: 10.3389/fimmu.2021.649441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
27 Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 2020;9:E4034. [PMID: 33322221 DOI: 10.3390/jcm9124034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
28 Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. J Clin Med 2020;9:E3859. [PMID: 33261023 DOI: 10.3390/jcm9123859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
29 Röth A. Do temperature and time matter in cold agglutinin disease? Blood 2020;136:380-1. [DOI: 10.1182/blood.2020006566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Tomkins O, Berentsen S, Arulogun S, Sekhar M, D'Sa S. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol 2020. [PMID: 32652632 DOI: 10.1002/ajh.25932] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]